同步辐射微束放疗联合宽束放疗在临床前三阴性乳腺癌模型中的影响
在4T1.2小鼠乳腺肿瘤模型中,比较300 Gy峰剂量/7 Gy谷剂量微束放疗(MRT)与8 Gy宽束放疗(BB)不同联合方案的局部肿瘤反应和转移负荷。单次MRT加入BB方案改善了原发肿瘤反应,但各方案转移负荷相似,动物生存仅一个联合方案略延长。
要点
- 单次MRT联合BB较单纯BB改善局部肿瘤控制且耐受性良好。
- 所有四种治疗方案的转移负荷相似。
- 动物生存仅一个联合方案略有延长。
核心结论
- 在BB治疗中加入单次MRT改善了原发肿瘤反应。
- 这为未来结合辅助免疫治疗或化疗以改善局部和全身治疗结局的实验提供了基础。
研究设计与样本
- 临床前研究,使用4T1.2小鼠乳腺肿瘤模型。
- 治疗方案为300 Gy峰剂量/7 Gy谷剂量MRT和/或8 Gy BB放疗,均以每日分次方案给予(连续3天每日一次MRT或BB,或1次MRT联合2次BB,MRT位于3次分次中的第一次或最后一次)。
- 小鼠在末次照射后第9天安乐死,此时未照射对照动物达到伦理终点。
- 收集原发肿瘤评估免疫细胞丰度,收集肺、脊髓和局部区域淋巴结测量转移负荷,同时监测局部肿瘤生长和生存。
主要发现
- 联合MRT/BB治疗使肿瘤内促肿瘤与抗肿瘤巨噬细胞的平衡向抗肿瘤巨噬细胞积累方向偏移。
- 肿瘤体积和动物健康监测表明联合MRT/BB治疗有利于局部控制 and 治疗耐受性。
- 动物生存仅在一个联合方案中略有延长。
- 所有4种治疗方案的转移负荷相似。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Both local tumor control and distant metastasis are important indicators of the efficacy of radiation therapy treatment. Synchrotron microbeam radiation therapy (MRT), spatially fractionated radiation delivered at ultrahigh dose rates, shows remarkable normal tissue sparing with excellent local control in some models. Some MRT regimens trigger an antitumor immune response that contributes not only to the local but also to systemic treatment efficacy. Despite recent advances in the treatment of primary breast cancer, metastatic disease is still the major cause of treatment failure in the clinic. Here, in an aggressive preclinical triple-negative breast cancer model, we compared local tumor response and metastasis following different MRT treatment programs. METHODS AND MATERIALS: 4T1.2 mouse mammary tumors were treated with 300 Gy peak/7 Gy valley dose MRT and/or 8 Gy broad beam (BB) radiation, all delivered as daily fractionated programs (3 consecutive daily sessions of either MRT or BB or 1 MRT combined with 2 BB sessions, the first or last of the 3 fractions). The mice were euthanized on day 9 post last irradiation, when unirradiated control animals reached an ethical endpoint. Primary tumors were collected to evaluate immune cell prevalence, while lungs, spinal cords, and locoregional lymph nodes were collected to measure metastatic burden. In parallel, local tumor growth and survival were monitored. RESULTS: The combined MRT/BB treatment shifted the balance between pro- and antitumorigenic macrophages toward the accumulation of antitumorigenic macrophages in the tumor. Monitoring of the tumor volume and animal health indicated the benefit of the combined MRT/BB treatment for local control and treatment tolerance, while animal survival was only marginally longer for one combined schedule. The metastatic burden was similar for all 4 treatment schedules. CONCLUSIONS: The addition of a single MRT to BB treatment improved the primary tumor response. This provides a basis for future experiments incorporating adjuvant immunotherapy or chemotherapy to improve local and systemic treatment outcomes.
引用
- Engels E, Forrester H, Klein M, et al. The Impact of Synchrotron Microbeam Radiation Therapy Combined With Broad Beam in a Preclinical Breast Cancer Model. Adv Radiat Oncol. 2024. PMID: 39687472. doi:10.1016/j.adro.2024.101680
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。